Dei BioPharma has unveiled its next bold phase, announcing the commencement of Active Pharmaceutical Ingredient (API) manufacturing at its state-of-the-art facility in Matugga, on the outskirts of Kampala city.
This massive undertaking, unveiled over the weekend by Dr. Mathias Magoola, the Dei BioPharma Managing Director, is not just a commercial venture but a continental commitment aimed at radically reducing Africa’s crippling dependence on imported medicines and achieving genuine healthcare self-reliance.
Hub of Pharmaceutical Excellence at Matugga
According to Dr. Magoola, the Dei BioPharma facility in Matugga is setting new global benchmarks for pharmaceutical manufacturing.
Spanning over 250 acres and housing more than 26 manufacturing units, the facility is designed to meet the rigorous standards of the US FDA, EMA, and WHO GMP.
Dr. Magoola asserted that the strategic scope of production is comprehensive, focusing on areas critical to public health across Africa that include:
Essential Generic Medicines: Production of high-demand drugs like Paracetamol, Metformin, Metronidazole, and Doxycycline.
Advanced Biologics: Manufacturing complex Monoclonal Antibodies (Bevacizumab, Rituximab) for cancer treatment.
Vaccine Production: Targeted production for diseases including Hepatitis B, C, and Tetanus.
Diagnostics and Excipients: Localised production of in-vitro diagnostic kits tailored for African diseases, and the use of cassava-based excipients (starch, sucrose, fructose) leveraging indigenous knowledge.
Continental Ambition Backed by Global Funding and African Demand
To achieve the pharma’s objectives, Dr. Magoola noted that Dei BioPharma’s mission is strategically aligned with the continent’s ambition for health security. Its long-term goals are staggering, and they include:
To produce over 1 billion doses of mRNA vaccines annually, and
To deliver therapies for major diseases, including HIV/AIDS, malaria, and cancer.
He explained that the initiative is strongly supported by both African and international partners, who include:
Africa CDC Commitment
Senior scientists representing the Africa Center for Disease Control (CDC) recently visited the Matugga facility, expressing their firm commitment to Uganda’s pharmaceutical ambition.
Massive Pledged Funding
The venture is bolstered by over US$2 billion in pledged funding, including a substantial US$1.2 billion from Gavi, specifically to empower African manufacturers who achieve the WHO prequalification standards.
Predictable Market
A crucial procurement mechanism, according to Dr. Magoola, is being finalised to pool demand across all 55 African Union member states. This collective purchasing strategy, he contends, guarantees a predictable and sustained market for locally manufactured medicines, making local production economically viable.
The Matugga facility is more than just a factory; it is a manifestation of a continental vision, one that leverages modern science, global standards, and indigenous knowledge to build a healthier, stronger, and more resilient Africa.